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Abstract The liver is a major metastasis-susceptible site
and majority of patients with hepatic metastasis die from
the disease in the absence of efficient treatments. The
intrahepatic circulation and microvascular arrest of cancer
cells trigger a local inflammatory reaction leading to cancer
cell apoptosis and cytotoxicity via oxidative stress media-
tors (mainly nitric oxide and hydrogen peroxide) and
hepatic natural killer cells. However, certain cancer cells
that resist or even deactivate these anti-tumoral defense
mechanisms still can adhere to endothelial cells of the hepatic
microvasculature through proinflammatory cytokine-mediated
mechanisms. During their temporary residence, some of these
cancer cells ignore growth-inhibitory factors while respond to
proliferation-stimulating factors released from tumor-activated
hepatocytes and sinusoidal cells. This leads to avascular
micrometastasis generation in periportal areas of hepatic
lobules. Hepatocytes and myofibroblasts derived from portal
tracts and activated hepatic stellate cells are next recruited into
some of these avascular micrometastases. These create a
private microenvironment that supports their development
through the specific release of both proangiogenic factors and
cancer cell invasion- and proliferation-stimulating factors.
Moreover, both soluble factors from tumor-activated hepato-
cytes and myofibroblasts also contribute to the regulation of
metastatic cancer cell genes. Therefore, the liver offers a
prometastaticmicroenvironmenttocirculatingcancercellsthat
supports metastasis development. The ability to resist anti-
tumor hepatic defense and to take advantage of hepatic cell-
derived factors are key phenotypic properties of liver-
metastasizing cancer cells. Knowledge on hepatic metastasis
regulation by microenvironment opens multiple opportunities
for metastasis inhibition at both subclinical and advanced
stages. In addition, together with metastasis-related gene
profiles revealing the existence of liver metastasis potential in
primary tumors, new biomarkers on the prometastatic micro-
environment of the liver may be helpful for the individual
assessment of hepatic metastasis risk in cancer patients.
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Introduction
The liver is the second most commonly involved organ by
cancer metastasis, after the lymph nodes. The true preva-
lence of metastatic liver disease is unknown but, depending
on the site of the primary tumor, 30–70% of patients dying
of cancer have hepatic metastases. The liver may be the site
of metastasis from virtually any primary malignant tumor,
and the most common primary sites are uveal melanoma,
gastrointestinal cancers, breast and lung carcinomas, neuro-
endocrine tumors and sarcomas. In children, the most
common liver metastases are from neuroblastoma, Wilms
tumor, or leukemia [1].
In Europe and North America, a focal liver lesion is
more likely to represent a metastatic tumor than a primary
malignancy. However, most liver metastases are multiple,
involving various lobes in 77% patients, and only 10% are
solitary. In addition, multiple tumors often vary in diameter
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patients with hepatic metastases still will die of their disease
and surgical resection offers around a 50% 5-year survival
rate to selected patients with hepatic metastases [2].
Numerous studies have focused on factors determining
metastasis recurrence to the liver, but at the moment, the
genetic and phenotypic properties of specific cancer cells
able to implant and grow in the liver have not yet been
established for any tumor type. Neither is it known the
contribution of the heterogeneous biologic backgrounds
from individual patients to hepatic metastasis diathesis and
regulation.
In this review we summarize our current knowledge on
the pathogenic mechanisms of hepatic metastasis in order to
define the contribution of architectural and functional
aspects of the hepatic microenvironment to the regulation
of infiltrating cancer cells. Four consecutive phases and
their specific mechanisms were considered in this review
during hepatic metastasis development (Table 1). Then, the
role of both the hepatic microvascular structure and the
functional heterogeneity of hepatic parenchymal and non-
parenchymal cell types in the regulation of metastatic
cancer cells were analyzed. Particular emphasis was done
on the contribution of tumor-activated hepatic cells and
tumor-induced hepatic inflammation to cancer–hepatic cell
interactions leading to immune escape, intratumor stromal
and angiogenic cell recruitment and gene expression and
growth of metastatic cells. However, it has to be mentioned
that most of available information derives from experimen-
tal hepatic metastasis models and, therefore, needs to be
clinically validated.
Why Cancer Cells Metastasize to the Liver?
Since the end of the nineteenth century, two non-excluding
theories have been considered to explain the phenomenon
of organ-specific spreading of cancer cells [3]. First, it is a
process directed passively due to mechanical factors that
result from the anatomical arrangement of the vascular
system, the blood flow rate and the nonspecific trapping of
cancer cells by microvascular size constraints—Ewing’s
Theory [4]—. Second, the process is due to a fertile
environment provided by the organ in which cancer cells
can survive and proliferate—Paget’ Seed and Soil Theory
[5]—. In the case of the liver, both anatomical/hemody-
namical and functional (microenvironmental) factors work
together to trap and kill circulating cancer cells, but also to
make this territory one of the most common sites for cancer
metastasis.
On the one hand, the liver’s important role within the
circulatory system makes it a common stopping point for
tumor cell emboli carried in the blood from tumors located
in other organs. The liver filters the venous drainage from
the majority of intra-abdominal viscera and around 30% of
the cardiac output. In addition, hepatic microcirculation is
slow and tortuous due to the anastomotic arrangement of
networking sinusoidal capillaries within hepatic lobules
(Fig. 1), and to the blood flow control role of intrasinusoidal
macrophages—Kupffer cells—and perisinusoidal stellate
cells [6]. These features confer the hepatic territory with a
great accessibility for circulating cancer cells, but also with
an efficient filtration capability facilitating the mechanical
arrest of the majority of circulating cancer cells.
On the other hand, the microenvironment of the liver is
biologically unique (Fig. 2a–c). First of all, fenestrated
endothelial cells and organ-specific macrophages (Kupffer
cells) lining hepatic sinusoids constitutively express a rich
profile of surface oligosaccharides [7], cell adhesion
proteins [8], and recognition receptors for a variety of
pathogen-associated molecular patterns [9], and are
endowed with very efficient receptor-mediated endocytotic
mechanisms [10]. These properties are cytokine-inducible
[11, 12] and account for the efficient hepatic uptake and
clearance of circulating waste molecules, death cells,
microorganisms, and even cancer cells. Second, the liver
also contains a large resident population of activated
defense cells—including macrophages [13], dendritic cells
[14], mast cells [15], cytotoxic natural killer (NK) cells and
Table 1 Phases and major mechanisms of the hepatic metastasis
process
1. The microvascular phase of liver-infiltrating cancer cells
Cancer cell retention and death in the hepatic microvasculature.
Cancer cell survival and adhesion to the hepatic microvasculature.
Cancer cell extravasation.
Tumor-induced inflammation and immune suppression.
Anti-tumor cytotoxicity of liver-associated lymphocytes.
2. The intralobular micrometastasis phase
Onset of cancer cell growth at periportal areas of hepatic lobules.
Stromal cell recruitment into avascular micrometastases.
Hepatic stellate cell activation by tumor-derived factors.
Role of tumor-activated hepatocytes.
3. The angiogenic micrometastasis phase
Proangiogenic effects of intrametastatic stroma.
Role of hypoxia.
Role of tumor-derived factors.
Hepatic metastasis angiogenic patterns.
Replacement/Sinusoidal-type metastasis.
Pushing/Portal-type metastasis.
4. The established hepatic metastasis phase
Development and effects of tumor-infiltrating stromal cells.
Pathophysiology of unaffected hepatic areas.
Hepatic metastasis-related genes.
Genes encoded at the primary tumor
Hepatic microenvironment-dependent genes
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immune response, while are maintaining a tolerogenic state
to avoid chronic inflammation [17, 18]. In turn, hepatic
immune tolerance may be responsible for the increased
prevalence of autoimmunity, infectious diseases and malig-
nancies, because the hepatic territory does not significantly
object the implantation and growth of microorganisms—as
for example malaria sporozoites [19], fungi [20], progenitor
hematopoietic cells [21], and even cancer cells. Third, the
liver contains a heterogeneous population of parenchyma
cells—hepatocytes and cholangiocytes—and non-parenchymal
stromal cells—mainly portal fibroblasts and perisinusoidal
stellate cells— [22, 23]. These cells can contribute to intra-
tumoral stroma and blood vessel generation in response to
tumor-derived factors, providing a favorable milieu for the
survival and growth of cancer cells from outside the liver.
Therefore, concomitant to anatomical and hemodynamical
features facilitating the intrahepatic lodgment of circulating
cancer cells, it appears that the functional microenvironment
createdbyhepaticcellsmayfurthercontributetoretentionand
destruction of circulating cancer cells, but also to facilitate the
ability of some of them to grow in the liver as a metastasis.
The availability of methods for isolating and primary
culturing hepatic parenchymal and non-parenchyma cells
has greatly facilitated the research on molecular mecha-
nisms of cancer-host cell interactions in the liver using in
vitro models. New features of the hepatic metastasis
microenvironment have been uncovered and molecular
targets of interest for anti-tumor therapeutic innovation
have been identified using these experimental models.
However, if the same microenvironmental factors operate
for every metastasis, irrespective of the tumor type, and if
we can prevent or treat hepatic metastasis by blocking
hepatic prometastatic factors, or by upregulating anti-
metastatic factors from the hepatic microenvironment,
needs further preclinical research prior to the clinical
translation.
Once circulating cancer cells have reached the liver,
metastasis generation depends on the sum of well-defined
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Fig. 1 Scanning electron microscopic image on the hepatic lobule.
The hepatic lobule has the form of a polyhedral prism that in this
picture has been sectioned horizontally. At the lobule corners, portal
tracts are situated containing terminal portal veins (TPV), perilobular
arteries, lymphatic vessels, nerve fibers and bile ducts (not visible).
TPV surround the lobule and are also connected to sinusoids through
occasional gates serving for the intralobular access of blood (arrows).
Hepatic parenchymal cells—hepatocytes (H)—are organized in plates
radially arranged around the centrilobular vein (CLV) located in the
center of the hepatic lobule. Sinusoids (S) form a microvasculature
among hepatocytes within the hepatic lobules. They form an
anastomotic network in the periportal area, while are straits in the
centrilobular area around the central vein. Blood passes through
openings in the TPV into sinusoids and circulates among hepatocytes
to be collected by the CLV. There, blood continues to the interlobular
veins and, then, into collecting veins draining finally into the hepatic
veins leaving the liver through the suprahepatic vein (not shown). Bar:
50 μm
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Fig. 2 Scanning electron microscopic images on the intrahepatic
pathway of metastatic cancer cells. a Cross section of a 9-μmi n
diameter hepatic sinusoid (S), lined by the fenestrated sinusoidal
endothelium (E), and surrounded by hepatocytes (H), bar:5μm. b An
intrasinusoidal Kupffer cell occupying the sinusoidal lumen and
connected to the endothelial wall by filopodia and a long citoplasmic
prolongation (arrows), bar:5μm. c Fenestrated surface of the hepatic
sinusoidal endothelium. Under physiological conditions, endothelial
fenestrae are transcellular structures of 100–150 nm in diameter that
cluster forming highly filtrating microdomains named sieve plates,
bar:1μm. d Mouse liver tissue on the fifth day post-intrasplenic
injection of Lewis lung carcinoma cells. Circulating cancer cells first
interact with non-fenestrated endothelial cells and adhered leukocytes
and macrophages at perilobular terminal portal veins (TPV). Pre-
sinusoidal gates for intralobular access of cancer cells (S). Intra-
sinusoidal retention of cancer cells (arrows) within the periportal area
of the hepatic lobule. Surrounding hepatocytes (H) and endothelial
cells (E) lining sinusoids (S). Bar:1 0μm
The prometastatic microenvironment of the liver 115colonization phenomena that a very small fraction of liver-
infiltrating cancer cell clones appear to successfully
accomplish. The complexity of involved mechanisms and
the control role of microenvironmental factors make hepatic
metastasis a highly inefficient process for cancer cells [24]
that frequently leads to incomplete metastases, without
clinical impact due to their stromal and angiogenic
deficiencies. Below is analyzed the sequence of interrelated
mechanisms contributing to the development of hepatic
metastasis. These have been aggregated into four patho-
physiological rate-limiting phases that may demand differ-
ent treatment strategies.
The Microvascular Phase of Liver-infiltrating
Cancer Cells
It includes the mechanisms of occult intravascular arrest,
death and survival of liver-infiltrating cancer cells, and their
interaction with sinusoidal cells via inflammation-mediated
mechanisms.
Cancer Cell Retention and Death in the Hepatic
Microvasculature
The hepatic metastasis process begins with the microvas-
cular retention of circulating cancer cells. Cancer cell
clumps reaching the liver normally arrest in the terminal
portal venules that surround hepatic lobules, while single
cancer cells can also arrest in the proximal segments of
sinusoids located in the periportal area of hepatic lobules
[25, 26]. This happens when single cancer cells pass
through pre-sinusoidal sphincters regulating blood access
to intralobular sinusoids (Fig. 2d). Intravital videomicro-
scopy and confocal microscopy on cancer cells experimen-
tally delivered to the portal circulation [27, 28] have
demonstrated that this step is in part regulated by sinusoidal
structure and hemodynamical mechanisms at same time
promoting microvascular arrest and destruction of cancer
cells. Not surprisingly, very few of the cancer cells
delivered to periportal areas travel along sinusoids to
centrilobular areas and reach the lungs in a viable state
[29]. Very few cancer cells (around 0.5%) may also traverse
the liver through portal-centrilobular venous shunts and
implant in the lung [27]. Therefore, deformation-associated
trauma and mechanical stress, suffered by cancer cells on
entry and residence in the hepatic microvasculature, are
important factors contributing to cancer cell death [30, 31].
Infiltrating cancer cells can also induce obstruction of
affected sinusoidal segments (Fig. 3a), leading to blood
flow blockade and transient micro-infarcts at specific sites
of cancer cell inflow and arrest. This mainly occurs in the
periportal segment of hepatic sinusoids and can damage
sinusoidal cells and even parenchymal cells (Fig. 1d). In
turn, re-oxygenation of these ischemic sinusoids induces
the proinflammatory activation of sinusoids affected by
cancer cell trapping [32], leading to additional killing of
cancer cells in the following hours, as a result of the release
of nitric oxide [33] and reactive oxygen intermediates [34]
by hepatic sinusoidal cells. Moreover, nitric oxide-induced
tumor cytotoxicity is increased by sinusoidal cell produc-
tion of hydrogen peroxide due to the formation of potent
oxidants, likely OH and NO3 radicals, via a trace metal-
dependent process [35].
When cancer cells invade the liver, they also encounter
defense mechanisms specific to the organ, operated by the
orchestrated actions of Kupffer cells, hepatic NK cells and
endothelial cells. Kupffer cells can phagocytose and clear
cancer cells [36–38]. Using CC531 colon carcinoma cells,
it has been reported that cancer cell clearing may be done
by a minority of Kupffer cells mainly located in the
periportal area of hepatic lobules [39]. Kupffer cells can
also modulate the host immune response to cancer cells by
releasing cytotoxic products and immune stimulating
factors, such as interferon-gamma, that activate hepatic
NK cells [16, 40]. In turn, these cells produce anti-tumor
cytotoxicity via perforin/granzyme-containing granule secre-
tion and death receptor-mediated mechanisms, including Fas/
FasL pathway [41, 42].
Therefore, the special arrangement of sinusoids in the
periportal areas of hepatic lobule, in combination with the
preferential location of cytotoxic and phagocytotic cells in
this precise territory account for the removal of most
circulating cancer cells passing through the liver after
leaving their primary tumor. These early microvascular
events may serve to severely limit further direct spread of
liver-infiltrating cancer cells to other organs, and therefore
may contribute to metastatic inefficiency of disseminated
tumors. However, some arrested cancer cells can resist to,
and even deactivate, the hepatic anti-tumor microenviron-
ment. For example, when cancer cell arrest occurs in
clumps inner cells are protected to attacks from anti-tumor
immune defenses. In the case of colorectal carcinoma cells,
tumor-derived carcinoembryonic antigen can prevent can-
cer cell death by inducing IL-10 to inhibit inducible NO
synthase upregulation in hepatic cells and NO-dependent
cancer cell death [43, 44]. Expression of major histocom-
patibility complex (MHC) class I on colon carcinoma cells
is a mechanism of immune escape that can also negatively
regulate hepatic NK cell-mediated apoptosis and cytolysis
by blocking the perforin/granzyme pathway [45], leading to
incomplete killing by NK cells of intrasinusoidal colon
carcinoma cells. In the case of metastatic melanoma, the
high intracellular level of glutathione protects B16 mela-
noma cells from oxidative stress induced by sinusoidal cell-
derived factors, contributing to cancer cell survival within
116 F. Vidal-Vanaclochathe hepatic microvasculature [46]. This mechanism appears
highly dependent on the glutathione peroxidase/glutathione
reductase system required to eliminate hydrogen peroxide
[47].
Cancer Cell Survival and Adhesion to the Hepatic
Microvasculature
Certain liver-infiltrating cancer cells that survive in the
hepatic microvasculature are able to interact with sinusoid-
lining endothelium and Kupffer cells [48] (Fig. 3b). This
occurs via soluble paracrine and juxtacrine factors and leads
to the firm adhesion of certain cancer cells to the sinusoidal
wall. The adhesion mechanism is further upregulated by
endogenous proinflammatory factors and reactive oxygen
metabolites, released or induced by cancer cells in the
hepatic sinusoid microenvironment [49–51]. Endotoxins
released by gastrointestinal bacteria to the portal circula-
tion, and exogenous pro-inflammatory cytokines and drugs
can also stimulate the adhesion of cancer cells to the hepatic
microvasculature [52]. However, the proinflammatory
response appear to be tumor-specific, and even just some
few cancer cell subpopulations within a given tumor may
directly release proinflammatory factors or induce their
release from hepatic cells.
The experimental hepatic colonization of B16 melanoma
cells supports the important prometastatic implications of
inflammatory cytokine-dependent cancer-sinusoidal cell
interactions. Using intrasplenically injected B16F10 mela-
noma cells, we showed that the expression of VCAM-1
significantly increased in hepatic sinusoidal endothelium
cells within the first 24 h of metastatic cancer cell
infiltration in the liver. In vivo VCAM-1 blockade with
specific antibodies prior to B16 melanoma cell injection
decreased microvascular retention of luciferase-transfected
B16 melanoma cells by 85%, and metastasis development
by 75%, indicating that VCAM-1 expression on tumor-
activated hepatic sinusoidal endothelium cells had a
prometastatic role [53]. Interestingly, in primary cultured
hepatic sinusoidal endothelium cells treated with B16
melanoma-conditioned medium, a proinflammatory cyto-
kine cascade occurred in which TNF-alpha induced IL-
1beta; then, IL-1beta, either alone or with TNFalpha,
induced IL-18 release [54]. Neither TNF-binding protein
nor IL-1 receptor antagonist were able to inhibit the
increase in adhesiveness in IL-18-treated hepatic sinusoidal
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Fig. 3 Confocal microscopy on experimental cancer cell entry and
residence in the hepatic microvasculature. Carboxyfluorescein-labeled
CT26 murine colorectal carcinoma cells were intrasplenically injected
in syngeneic mice and their livers were perfused on the 24th and 48th
hour with fluorescence-labeled wheat germ agglutinin (WGA), as
previously described [7], for the specific staining of hepatic
microvascular walls (cancer cells had not WGA-binding sites. a
Retention of a cancer cell (in green) in the lumen of a hepatic sinusoid
(in red). Notice that the body of the cancer cell completely occupied
the sinusoidal lumen preventing endothelial cell labeling with the
perfused lectin beyond this point. b Cancer cell adhesion to the
endothelial wall of a periportal sinusoidal segment. c Onset of cancer
cell proliferation on the 48th after injection. Notice that cancer cell
clump did not alter microvascular staining in the area, suggesting the
extravascular position of cancer cells. Terminal portal vein (TPV);
sinusoid (S); cancer cells (arrows). Bar:2 0μm
The prometastatic microenvironment of the liver 117endothelium cells, confirming that neither endogenous
TNFalpha nor IL-1 mediated IL-18-induced endothelial
cell adhesiveness. Conversely, IL-18 neutralization by
using IL-18 binding protein [53] did not reduce tumor-
induced TNF-alpha or IL-1beta release from endothelial cells,
suggesting that their production was IL-18-independent. As
such, TNFalpha and IL-1beta used the production of IL-18 to
facilitate the increase in endothelial cell expression of
VCAM-1forarrestingcancercellsduringtheirtransitthrough
the hepatic microvasculature (Fig. 4).
Recombinant catalase also abrogated the proadhesive
response of hepatic sinusoidal endothelium cells to B16
melanoma cell-conditioned medium, although this did not
affect the release of major proinflammatory cytokines by
tumor-activated hepatic sinusoidal endothelium cells [51].
In turn, hydrogen peroxide production from B16 melanoma
conditioned medium-treated endothelial cells was regulated
by IL-18 [53]. Thus, liver-infiltrating B16 melanoma cells
activated their adhesion to hepatic sinusoidal endothelium
cells through a sequential process involving TNF-alpha-
dependent IL-1beta, which induced IL-18 to up-regulate
VCAM-1 via hydrogen peroxide. This cytokine cascade
can be induced by tumor-derived VEGF [54]. In addition,
the pivotal position of IL-18-induced hydrogen peroxide
was further supported by the fact that incubation of hepatic
sinusoidal endothelium cells with nontoxic concentrations
of hydrogen peroxide directly enhanced VCAM-1-dependent
B16 melanoma cell adhesion in vitro without proinflamma-
tory cytokine mediation, which emphasizes the key role of
oxidative stress in the pathogenesis of IL-18-dependent
hepatic metastasis. Consistent with these findings, hepatic
metastasis of intrasplenically injected B16 melanoma cells
dramatically reduced in IL-1beta KO mice and almost
completely inhibited in ICE KO mice [48]. Moreover, a
single intraperitoneal dose of naturally occurring IL-18
binding protein given 30 min before intrasplenic injection
of B16F10 cells abolished VCAM-1 up-regulation in the
hepatic microvasculature and reduced hepatic metastasis by
80% [55]. These data demonstrate a significant role of
endogenous IL-18 on hepatic metastasis by up-regulating
melanoma cell adhesion to hepatic sinusoidal endothelium
cells, implicating a possible antimetastatic benefit of neu-
tralizing IL-18 [56]( F i g .3).
Khatib et al. [57] also detected that metastatic murine
lung carcinoma H-59 or human colorectal carcinoma CX-1
cells triggered TNF-alpha production by Kupffer cells
located in sinusoids around the invading cancer cells,
during the initial stages of liver metastasis. This was
followed by increased expression of the vascular adhesion
receptors E-selectin, P-selectin, VCAM-1, and ICAM-1 on
sinusoidal endothelium cells. This proinflammatory response
was tumor-specific and was not observed with nonmetastatic
cancer cells. Again, these results identify sinusoidal cell-
mediated TNF-alpha production as an early, tumor-selective
host inflammatory response to liver-invading cancer cells
that may influence the course of metastasis. Interestingly,
over-expression of secretory leukocyte protease inhibitor—a
factor attenuating inflammatory response by blocking NF-
kappaB-mediated TNF-alpha—in highly metastatic subline
(H-59) markedly decreased the ability of these cells to elicit
a proinflammatory response in the liver and to form hepatic
metastases [58].
Using a combination of immunohistochemistry, confocal
microscopy, and three-dimensional reconstruction, Auguste
et al. [59] also evidenced E-selectin expression mainly on
sinusoids by 6 and 10 h, respectively, following murine H-
59 and human CX-1 carcinoma cell inoculation. Cancer
cells arrested in E-selectin expressing endothelial cells and
appeared to flatten and traverse the sinusoidal lining, away
from sites of intense E-selectin staining. This process was
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Fig. 4 Tumor-induced
proinflammatory factors regulate
melanoma cell adhesion to
hepatic sinusoidal endothelium
prior to metastasis formation
118 F. Vidal-Vanaclochaevident by 8 (H-59) and 12 h (CX-1) after inoculation,
coincided with increased endothelial VCAM-1 expression,
and involved tumor cell attachment in areas of intense
VCAM-1andPECAM-1expression.Non-metastatic(human)
MIP-101 and (murine) M-27 cells induced a weaker response
and could not be seen to extravasate. The results show that
metastatic cancer cells can use newly expressed endothelial
cell receptors to arrest and extravasate.
Therefore, cytokine release from tumor-activated sinu-
soidal cells can be identified as an early, tumor-specific
inflammatory response to liver-invading cancer cells, that
may influence metastasis occurrence. In addition, factors
that either attenuate tumor-induced host proinflammatory
response or adhesion receptors for cancer cells may have a
therapeutic potential in the prevention of liver metastasis.
Tumor-induced Inflammation Inhibits Anti-tumor
Cytotoxicity of Liver-associated Lymphocytes
Tumor-induced hepatic inflammation also involves up-
regulation of mannose receptor (ManR)-mediated endocy-
tosis [60], a 175 kDa transmembrane glycoprotein involved
in the general processes of endogenous defense [61]. ManR
binds and uptakes mannosylated molecules and circulating
infectious agents, and contributes to the mechanisms of
cancer cell adhesion and antigen processing and presenta-
tion to lymphocytes [62, 63]. ManRs are also involved in
antigen uptake and presentation to T cells by hepatic
sinusoidal endothelium cells and it has been suggested that
this process underlies the well-known immune-tolerance
occurring in the liver under physiological conditions. Using
murine C26 colon carcinoma cells, we demonstrated that
ManR expression and endocytotic activity increased in
hepatic sinusoidal endothelium cells upon direct interaction
with metastatic C26 cells [60]. The mechanism required
COX-2-dependent production of IL-1-stimulating factor(s)
from tumor cells activated by membrane or soluble ICAM-
1. In turn, IL-1-induced ManR led to decreased cytotoxicity
in liver lymphocytes interacting with tumor-activated
endothelium. This suggests the contribution of mannose
receptors to immune suppression during the hepatic
colonization of cancer cells, and the secretion of ManR-
stimulating factor(s) as a new prometastatic feature of liver-
metastasizing cancer cells.
The Intralobular Micrometastasis Phase
It starts with the growth activation of cancer cells evading
local immune defense; either intravascularly located and
adhered to hepatic endothelial cells, or extravascularly
migrated into the Disse’s space and among hepatocytes
(Fig. 3c). Irrespective of the location, the proliferation of
surviving cancer cells occurs in periportal areas of the liver
lobule and results in the formation of subclinical avascular
micrometastases [28]. This phase is also supported by the
intrametastatic recruitment of perisinusoidal hepatic stellate
cells, portal fibroblasts and hepatocytes activated by tumor-
derived factors. These cells get integrated among metastatic
cancer cells forming a heterogeneous stroma that releases
paracrine growth factors for cancer cells, and creates a
preangiogenic stromal support [64].
The Prometastatic Microenvironment of Periportal Areas
within the Hepatic Lobule
Circulating cancer cell arrest, survival and growth activa-
tion is markedly affected by the functional zonation of the
liver lobule, leading to the selective generation of micro-
metastases in periportal areas [65]. Therefore, structural and
functional heterogeneity of parenchymal and sinusoidal
cells across the liver lobule, or acinus, represents an
obligated framework for understanding the contribution of
microenvironment to cancer cell regulation and micrometa-
stasis formation during the intralobular phase of the
metastatic process.
Liver zonation is characterized by phenotypic variations
of hepatocytes and sinusoidal cells along the length of the
sinusoid from the portal vein to the central vein (Fig. 5a).
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Fig. 5 Light microscopic image of hepatic tissue. a Parenchymal cell
heterogeneity across the hepatic lobule, as shown by immunohisto-
chemical staining of nerve growth factor-expressing hepatocytes. Bar:
100 μm. b Periportal micrometastases (arrows) from intrasplenically-
injected B16F10 melanoma cells. Terminal portal veins (TPV) and
centrilobular veins (CLV). Bar: 100 μm
The prometastatic microenvironment of the liver 119Oxygen tension, which decreases by about 50% from the
periportal to the perivenous regions, has been considered to
be a key regulator for zonated gene expression [66].
Gradients of metabolic substrates, hormones, and extracel-
lular matrix are thought to be other important regulators of
these zonal variations. These environmental variations have
implications for liver inflammation, fibrosis, aging, regenera-
tion and infection [67].
A very accurate method for calibrating the position
coordinates of initial micrometastatic foci in the hepatic acini
was made possible by using the succinate-dehydrogenase
reaction (Fig. 5b), which reveals the functional heterogeneity
of parenchymal cells within the hepatic lobule [68]. Based
on this approach we reported that experimental micro-
metastases occur in the periportal zone of liver lobules,
without being detected any significant differences resulting
from the cancer type (sarcoma, melanoma, carcinoma), its
metastatic potential (high and low), or the experimental
procedure used for obtaining the metastasis (subcutaneous or
intrasplenic injection). In subsequent experiments, metastasis
was induced after first altering the zonal distribution of the
hepatic extracellular matrix; distribution of the sinusoidal
macrophages; and the sinusoidal diameter. However, even
under these conditions, metastasis continued to occur
exclusively in periportal zones [69]. Thus, metastatic
predilection for this sublobular compartment cannot be
explained solely in terms of hemodynamic causes, or the
influence of extracellular matrix. On the contrary, the
functional microenvironment created by cells of the peri-
portal zone account for the metastatic predilection for
periportal zones [70]. For example, fenestration pattern,
expression of adhesion molecules, phagocytosis, receptor-
mediated endocytosis and antigen presentation by hepatic
sinusoidal cells have a zonal distribution across the acinus
[71, 72], and may influence the metastatic outcome of cancer
cells. Hepatocytes and hepatic stellate cells also express a
functional heterogeneity across the hepatic lobule [72]t h a t
may contribute to the periportal metastasis development.
Regulation of Initial Cancer Cell Growth
within the Hepatic Lobule Area
Many liver-infiltrating cancer cells remain dormant in an
extravascular position, while growth to form micrometa-
stases is initiated in only a small subpopulation of cancer
cells [28]. Therefore, activation of solitary dormant cancer
cell proliferation is a key event for hepatic metastasis
progression. Several mechanisms may operate at this level.
Firstly, when intravascularly located, cancer cell prolifera-
tion is activated by paracrine growth factors released by
neighboring tumor-activated endothelial cells. The mecha-
nism is significantly stimulated by proinflammatory cyto-
kines [49, 52]. Secondly, when extravascularly located,
cancer cell proliferation is activated by paracrine growth
factors released by neighboring tumor-activated hepato-
cytes and hepatic stellate cells. This is facilitated by
adhesive mechanisms [73] and junctional specializations,
such as desmosomes [74], formed between cancer cells and
hepatocytes, soon after invasion of the hepatic cell plate.
However, early micrometastatic foci may disappear after a
few days, and only a small subset may continue growth.
According to Groom et al. [75], critical mechanisms
responsible for cancer cell losses and metastatic ineffi-
ciency may also occur at this phase of micrometastatic
cell growth.
Stromal Cell Recruitment into Avascular Micrometastases
A rich tumor growth-stimulating stroma generated from
tumor-activated hepatic cells is recruited into developing
intralobular micrometastases. This is driven by cancer cell
releaseofstromalcellmigration-andproliferation-stimulating
factors. Three main sources of tumor-associated stromal cells
have been considered: (1) hepatic stellate cells [68, 76–78],
which transdifferentiates into myofibroblasts in response to
paracrine factors released by both cancer cells and tumor-
activated hepatic sinusoidal endothelium and Kupffer cells.
Once intrametastatic located, they express alpha-smooth
muscle actin, a marker for hepatic stellate cell activation
(Fig. 6a,b). This stromal cell origin mainly operates when
micrometastases are developed in the sinusoidal area of liver
lobules. (2) Portal tract fibroblasts [79], which contribute to
intrametastatic stroma when invading cancer cells are located
in the perilobular areas and are unable to activate the hepatic
stellate cell-dependent stromagenesis. (3) Hepatocytes,
which may suffer an epithelial to mesenchymal transition
induced by both tumor-derived factors and tumor-activated
hepatic stellate cell-derived factors, are also recruited into
metastatic tissue (Fig. 7a,b).
Whatever its tissue origin, intrametastatic stromal cells
exhibit a myofibroblast phenotype, and are already operating
in the avascular growth stage of developing hepatic
metastasis prior to angiogenic endothelial cell recruitment
[68]. There, bidirectional interactions involving paracrine
growth factors take place between cancer cells and stromal
cells supporting cancer cell invasion and proliferation.
Hepatic stellate cell-derived myofibroblasts mainly secrete
VEGF, platelet-derived growth factor-AB, hepatocyte
growth factor, PGE2 and transforming growth factor-beta.
Portal tract-derived myofibroblasts also produce IL-8, a
chemokine related to invasion and angiogenesis, in response
to TNF-alpha via nuclear factor-kappaB [79]. In the specific
case of hepatocytes, they also secrete several cancer cell
migration and proliferation-stimulating factors, and even
induce VEGF production from cancer cells. However, as
shown in a preliminary study using primary cultured
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metastasis, these prometastatic effects are heterogeneously
expressed among patients with established colon carcinoma
metastasis (Del Villar et al. submitted for publication).
The Angiogenic Micrometastasis Phase
It takes place in prevascular stromagenic micrometastases
having an average diameter larger than 300 μm, and
therefore, that are growing beyond the limits of liver
lobule. Main activities at this phase are intrametastatic
endothelial cell recruitment and blood vessel formation.
Proangiogenic factors from tumor-activated stromal cells
and hypoxic cancer cells initiate this phase [80]. Therefore,
it cannot occur in hypoxic hepatic micrometastases that did
not previously develop a myofibroblastic stromal support.
This angiogenic phase progresses stepwise as the hepatic
metastasis enlarges, and is a prerequisite for its continued
growth until it becomes a clinically visible established
metastasis.
Hypoxia Induces Proangiogenic Activation
of Intrametastatic Myofibroblasts
As above reported, infiltration of tumor-activated myofibro-
blasts precedes endothelial cell recruitment into avascular
micrometastases. Endothelial cell migration only occurred
towards avascular micrometastases containing a high
density of myofibroblasts and not towards metastases not
containing myofibroblasts (Fig. 8). Both myofibroblasts
and endothelial cells co-localized, and their densities
consistently correlated with the development of well-
vascularized metastases [80]. Because hypoxic tissue has
been identified as a potential source of angiogenic factors
within the tumor, we analyzed the effect of hypoxia on
myofibroblast production of angiogenic-stimulating factors.
As confirmed by pimonidazole staining, hypoxia occurred
in hepatic metastases of greater than 300 μm in diameter.
However, onset of myofibroblast recruitment occurred in
normoxic avascular micrometastases, whereas new intra-
tumoral capillaries are constituted once micrometastases
become hypoxic. In vitro, we [76] reported that hypoxia
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Fig. 6 a Two mechanisms are proposed for the hepatic stellate cell
activation by tumor-derived factors: Indirect, via tumor-activated
hepatic sinusoidal endothelial cells; direct, via transendothelial cell
diffusion of tumor-derived hepatic stellate cell-stimulating factors. b
Intratumoral recruitment of hepatic stellate cells (red stained) at the
intralobular micrometastasis phase of the experimental colonization of
intrasplenically-injected C26 colon carcinoma cells. Immunohisto-
chemical detection of smooth muscle-alpha actin reveals that intra-
metastatic, but not extrametastatic, hepatic stellate cells become
myofibroblasts by tumor-derived paracrine/juxtacrine factors prior to
angiogenesis occurrence. Terminal portal veins (TPV) surrounded by
portal tract fibroblasts and smooth muscle cells (in red). Bar:5 0μm. c
Panlobular C26 colon carcinoma micrometastasis containing a dense
population of tumor-activated myofibroblasts as revealed by immu-
nohistochemical detection of smooth muscle alpha-actin (stained in
brown). Bar: 100 μm. d High-magnification picture on smooth muscle
alpha-actin-expressing stromal myofibroblasts (MF) in an established
hepatic metastasis from a colorectal carcinoma patient. Tumor cells
(TC). Bar:1 5μm
The prometastatic microenvironment of the liver 121contributes to hepatic stellate cell production of VEGF,
which in turn increases endothelial cell migration, reduction
of apoptosis, and proliferation. Using an experimental
model of liver cirrhosis, Corpechot et al. [81] also reported
VEGF production by hypoxic hepatic stellate cell. Thus,
their recruitment under normoxic conditions, followed by
tumor growth-associated hypoxia, may constitute two
synergistic stimuli for intratumoral migration and survival
of endothelial cells during tumor blood vessel formation.
Interestingly, endothelial cell recruitment also follows the
penetration of hepatic stellate cells into hepatocyte clusters
of regenerating liver [82]. This physiologic mechanism of
tissue reconstitution may also account for the recruitment of
endothelial cells into micrometastases containing activated
hepatic stellate cells. Therefore, tumor-activated hepatic
stellate cells may promote blood delivery to liver metastasis
by triggering the onset of angiogenesis in avascular micro-
metastases and, then, by supporting their progressive
vascularization. Not surprisingly, hepatic stellate cells
exhibit pericyte-like functions [83] and their activation into
a myofibroblast-like phenotype is involved in several
hepatic disease processes associated to chronic and acute
liver injury [84].
Angiogenic Patterns in Developing Hepatic Metastasis
In an experimental model of hepatic metastasis by Lewis
lung carcinoma, Paku and Lapis [85] identified two types of
metastases with different angiogenic patterns: a sinusoidal
type, devoid of immunohistochemically detectable base-
ment membrane, and a portal type, located in the vicinity of
portal tracts, characterized by staining positively for
basement membrane components. Their association to
specific cancer cell implantation sites in the hepatic
microvasculature was further supported by the fact that
intrasplenically injected cancer cells (portal route) produced
only 18.2% of the portal type-metastases, whereas a
significantly higher percentage of the metastases (33.2%)
proved to be portal-type when cancer cells were injected
into the left ventricle (arterial route).
Consistent with these observations, Vermeulen et al. [86]
demonstrated that liver metastases from patients with
colorectal adenocarcinoma were also heterogeneous with
respect to angiogenesis and growth patterns. Three different
growth patterns were found in these liver metastases. In the
d e s m o p l a s t i ca n di nt h ep u s h i n gg r o w t hp a t t e r n s ,t h e
architecture of the liver parenchyma was not preserved. In
the replacement growth pattern, the reticulin pattern of the
liver parenchyma was conserved within the metastases at
the tumor-liver parenchyma interface. The replacement
growth pattern expanded with minimal angiogenesis by
co-opting the stroma with the sinusoidal blood vessels of
the liver. Indeed, the ratio of the proliferating cancer cell
fraction and the proliferating endothelial cell fraction,
roughly representing the degree of angiogenesis-dependent
growth, was three- to four-fold higher in the replacement-
type metastases compared with the other metastases. Cancer
cell apoptosis was highest in the pushing-type metastases
and was inversely correlated with microvessel density in
liver metastases.
Using several liver-metastasizing murine tumors (51b
and C26 colon carcinoma, PAM squamous cell carcinomas
and B16 melanoma), we also recognized two predominant
stromal patterns (Fig. 9), according to expression of alpha-
smooth muscle actin by intrametastatic myofibroblast-like
cells [87]: sinusoid-associated metastases, which contained
infiltrating, but not encapsulating, reticularly-arranged
myofibroblasts; and portal tract-associated metastases,
which were incompletely encapsulated, but not infiltrated,
by fibrous tract-arranged myofibroblasts. Based on reticulin
staining, the liver architecture was preserved in myofibro-
blast-infiltrated metastases because invasive cancer cells co-
opted the supportive fibrillar network of sinusoids, and,
thus, the limit between tumor and normal tissue was ill-
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Fig. 7 Low (a) and high (b) magnification pictures on the intra-
tumoral recruitment of hepatocytes in a C26 colon carcinoma
intralobular micrometastasis (MET). Tumor-activated perimetastatic
and intrametastatic hepatocytes (in brown) were immunohistochemi-
caly revealed by anti-mouse nerve growth factor (NGF) antibody.
Only cholangiocytes within the perilobular bile ducts and periportal
hepatocytes express NGF under normal physiological conditions.
However, tumor microenvironmental factors induced hepatocyte
expression of NGF. Bar: 100 μm( a) and 10 μm( b)
122 F. Vidal-Vanaclochadefined (equivalent to replacement-type). In contrast, the
reticulin network was not conserved within myofibroblast-
encapsulated metastases, because the enlarging mass of
cancer cells compressed surrounding parenchyma (pushing-
type) and generated the formation of tumor lobules
delineated by desmoplastic stroma (desmoplastic-type).
The precise mechanisms underlying different stromal
and angiogenic arrangements for replacement-/sinusoidal-
type and pushing-desmoplastic-/portal-type metastases remain
unclear. One possibility is that the myofibroblast-inducing
activities of cancer cells is dependent on the site of cancer cell
implantation, and that hepatic stellate cells represent the main
source of myofibroblasts for sinusoidal-type metastases,
whereas portal tract-derived fibroblasts constitute the stromal
support of portal-type metastases. This possibility is also
supported by the predominant expression of desmin and glial
fibrillary acidic protein—two hepatic stellate cell markers—by
myofibroblasts located in sinusoidal-type metastases [80];
while myofibroblasts located in portal-type metastases display
a vimentin and Thy-1 phenotype similar to resident portal
tract hepatic fibroblasts [79].
These stromagenic and angiogenic patterns are also
associated to aggressiveness and treatment resistance of
hepatic metastases. In this regard, hepatic metastases from
low metastatic squamous cell carcinoma PAM-212 cancer
cells replacedhepatocytes atthe cancer cell-liverparenchymal
cell interface, preserving the liver architecture, co-opting the
sinusoidal blood vessels and having a low fraction of
proliferating cancer cells; in contrast, hepatic metastases from
(highly-metastatic) PAM-LY2, the architecture of the liver
parenchyma was not preserved, stromagenic and angiogenic
activity derived from portal tracts and the fraction of
proliferating cancer cells was high. Interestingly, PAM-212
produced low concentrations of pro-angiogenic cytokines
while they released thrombospondin and insulin-like growth
factor binding protein-1. In contrast, PAM-LY2 cells pro-
duced a high amount of VEGF and GM-colony stimulating
factor. Therefore, specific cytokine patterns of these two
squamous carcinoma cell variants were associated to different
hepatic metastasis growth and angiogenesis patterns [88].
More importantly, anti-angiogenic agents did not similarly
affect sinusoidal-type and portal-type hepatic metastases.
Treatment of 51b colon carcinoma hepatic metastases with
recombinant human endostatin did not affect portal-type
metastases while it almost eradicated sinusoidal-type metas-
tases [87]. Similar results were recently obtained (Salado et
al., submitted) in hepatic metastases from B16 melanoma
treated with resveratrol, a natural product with anti-angio-
genic properties.
The Established Hepatic Metastasis Phase
Once liver-infiltrating cancer cells have accomplished the
three phases of the hepatic metastasis process, generated
tumors get the status of “established metastasis” whose
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Fig. 8 Immunohistochemical
detection of CD31-expressing
angiogenic endothelial cells in
portal-type (pushing growth
pattern) (a) and sinusoidal-type
(replacement growth pattern) (c)
hepatic metastases from intra-
splenically-injected head and
neck squamous cell murine
PAN-LY2 carcinoma cells. Im-
munohistochemical staining for
smooth muscle alpha actin ex-
pression of serial tissue sections
from the same livers (b and d).
Notice the co-localization of
CD31 and smooth muscle alpha
actin expressing cells in both
kinds of hepatic metastases.
Bar: 150 μm. e High-magnifi-
cation confocal microscopic im-
age on intrametastatic neo-
angiogenic vessels. CD31-
expressing endothelial cells
(green-stained) were surrounded
by smooth muscle alpha actin-
expressing vascular coverage
cells (red stained). Bar:2 0μm
The prometastatic microenvironment of the liver 123clinical detection will depend on the size, intrahepatic
location, blood flow alterations and aggressiveness. Even
for a given tumor type, established metastases are markedly
heterogeneous among patients and within the same patient.
Differences mainly concern the structure and density of
tumor-associated stroma and blood vessels [80], the
hemodynamic alterations in the portal vein and hepatic artery
[89], the phenotypic composition of tumor-infiltrating
lymphocytes [90], and the cancer cell profile with regard to
proliferation, invasion, gene expression and protein secre-
tion. However, at the moment the clinical and prognostic
significances of these biological aspects of hepatic metasta-
ses are unclear. Moreover, none of the identified gene
signatures [91, 92] or molecular markers has been success-
fully validated as a diagnostic or prognostic tool applicable
to routine clinical practice.
Hepatic Metastasis-related Genes
The development of established hepatic metastasis is
associated with overexpression or downregulation of
specific genes and cell regulatory pathways. Some of the
gene alterations may be originated in the primary tumor
and, thereafter, may support hepatic metastasis develop-
ment. In a recent study, Yamasaki et al. [92] investigated
the existence of liver metastatic potential in primary
colorectal tumors using metastasis-related genes detected
by chronological gene expression profiling of colorectal
samples corresponding to consecutive oncogenic stages.
Interestingly, the profile of metastasized primary tumors
resembled one of a metastatic lesion apart from a primary
lesion rather than one of a non-metastasized primary tumor.
Moreover, the expression profile of these genes allowed the
classification of tumors diagnosed as localized cancer into
two classes, the localized and the metastasized class,
according to their final metastatic status. The disease-free
survival and overall survival were significantly longer in
the localized class than the metastasized class suggesting
that the metastatic potential is already encoded in the
primary tumor and detectable, which allows the prediction
of liver metastasis in patients diagnosed with localized
tumors.
Other studies suggest that different microenvironments
can differentially affect the expression of metastasis-related
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Fig. 9 a Avascular micrometastasis (arrows) developed in the
sinusoidal domain of an hepatic lobule, surrounded by tumor-activated
hepatic stellate cells expressing smooth muscle alpha actin (red
stained cells). Terminal portal venule (TPV). Hepatocytes (H). Bar:
25 μm. b Sinusoidal-type hepatic micrometastasis (MET) at the
angiogenic phase, containing a dense network of sinusoidal neo-
vessels, as revealed by reticulin stain according to Gordon–Sweets
silver impregnation technique. Recruited microvessels form concentric
interconnections. Liver architecture is not disturbed, and cancer cells
co-opt the supportive fibrilar network of the sinusoids. Bar: 100 μm. c
Avascular micrometastasis (arrows) developed in close proximity to a
terminal portal vein (TPV) and surrounded by portal tract-derived cells
expressing smooth muscle alpha actin (red stained cells). Bar:2 5μm.
d Portal-type micrometastasis (MET) at the angiogenic phase. Here,
the reticulin network supporting intratumoral angiogenesis is not
conserved. Desmoplastic stroma surrounds and traverses metastasis,
facilitating invasion of vascular-type angiogenic vessels. Necrotic
areas frequently develop in this metastasis type. Bar: 100 μm
124 F. Vidal-Vanaclochagenes [93], and overexpression or underexpression of these
genes need not be present when cancer cells are in primary
tumors or initially disseminated. However, if the hepatic
microenvironment can regulate at a gene expression level
the ability of a cancer cell to metastasize is unclear. Using
RNA from hepatic metastases, tumor-unaffected hepatic
tissues and peripheral blood mononuclear cells from the
same patients we determined by DNA microarray and RT-
PCR the specific gene cluster representing the transcrip-
tome of cancer cells at the established hepatic metastasis
phase in patients with advanced colorectal carcinoma (Del
Villar et al. submitted for publication). This gene cluster did
neither include genes expressed by tumor-unaffected
hepatic tissues nor those from peripheral blood mononu-
clear cells from the same patients. To determine if hepatic
cells can still contribute to the regulation of hepatic
metastasis genes at established hepatic metastases, we
evaluated the transcriptome of HT-29 colon carcinoma cells
given the conditioned media from highly-prometastatic
hepatocytes and hepatic stellate cell-derived myofibro-
blasts. HT-29 cancer cells contained 235 genes upregulated
by hepatocyte-conditioned medium and 67 genes upregulated
by hepatic myofibroblast-conditioned medium. Majority of
genes upregulated by both hepatic cell types were different,
but a significant number of genes induced by each cell type
overlapped with those included in the specific gene cluster
representing the hepatic metastasis transcriptome from
patients with colon carcinoma. These results demonstrate the
differential contribution of hepatocytes and hepatic myofi-
broblasts to the microenvironmental regulation of hepatic
metastasis-related genes from colon carcinoma patients.
Consistent with tumor growth-stimulating properties of
hepatic stromal cells, around 50% of hepatic metastasis-
related genes regulated by soluble factors from hepatic cells
belonged to the cell cycle-regulation class further supporting
the role of these hepatic cells in the control of metastatic cell
proliferation.Hence,despitethepossibleexpressionofcertain
hepatic metastasis-related genes in the primary colorectal
tumors, that even may allow detecting metastasis risk in
cancer patients, tumor-activated hepatic cells may also
contribute to the expression of genes operating at established
hepaticmetastases.Thismicroenvironmentalcontroloccursat
an advanced phase of the hepatic metastasis process and,
therefore may have implications for therapy. Moreover, these
results demand research efforts to identify biomarkers on the
contribution of the hepatic biology backgrounds from
individual patients to hepatic metastasis development.
Conclusions
Certain circulating cancer cells are resistant to the specialized
anti-tumoral mechanisms of the liver microvasculature, while
take advantage of the hepatic microenvironment for develop-
ing metastases. The influence of the hepatic microenviron-
ment on the cancer metastasis process operates at various
levels, allowing the division of the hepatic metastasis process
in three microenvironment-associated stages that offer differ-
ent therapeutic opportunities (Table 2).
Hepatic Metastasis Stage I When the behavior of liver-
infiltrating cancer cells is mainly affected by the microvas-
cular anatomy and the functional zonation occurring within
the hepatic lobules or acini. This operates since the initial
arrest of circulating cancer cells in the hepatic microvascu-
lature until the formation of an avascular micrometastasis
that has not yet progressed beyond the limits of the hepatic
lobule because its diameter is smaller than 300 μm. At this
Table 2 Microenvironment-associated stages of the hepatic metastasis process
Features Stage I Stage II Stage III
Metastasis size <300 μm; not detectable 0.3 mm–5 mm; sometimes detectable >5 mm; detectable
Clinical impact Subclinical Organ-specific effects Systemic effects and risk of extrahepatic
dissemination
Metastasis phase Intralobular: Microvascular and
Avascular micrometastasis phases
Panlobular status: angiogenic phase Lobar status: established metastasis phase
Interaction with
hepatic cells
Avascular and stromal-free In cooperation with hepatic cells for
intrametastatic stroma and angiogenesis
development
Affected by both hepatic cells from tumor-
unaffected areas, and tumor-infiltrating
hepatic cells
Intrahepatic impact Cancer cells interact with hepatic
cells located in its original tissue
organization
Cancer cells interact with tumor-
infiltrating migratory hepatic cells
Cancer cells alter hepatic tissue structure,
blood supply and parenchymal cell
metabolism
Therapeutic targets Proinflammatory cytokines Angiogenic factors Tumor-growth factors
Immune suppressant factors Stromagenic factors Immune suppressant factors
Myofibroblast-stimulating factors
Oxidative stress-inducing factors
The prometastatic microenvironment of the liver 125stage, cancer cells interact with hepatic cells located in its
original tissue organization. This stage includes both the
microvascular and the avascular micrometastasis phases of
the hepatic metastasis process. Micrometastases are com-
pletely subclinical, avascular, sometimes even stromal-free,
and have not yet a significant influence on the functionality
of the whole organ. Therapeutic targets at this stage are
those factors inducing tumor-dependent hepatic inflamma-
tion and immune response inhibition, intrametastatic myofi-
broblast recruitment and endogenous antioxidant machinery
upregulation in cancer cells.
Hepatic Metastasis Stage II When liver-infiltrating cancer
cells have formed a micrometastasis whose mechanism of
development is no longer affected by hepatic zonation.
However, the process is still strongly hepatic cell-dependent
and requires the cooperation of hepatic cells for success-
fully developing intrametastatic stroma and angiogenesis.
This is the panlobular stage of the hepatic metastasis
process because it involves several hepatic lobules. Here,
cancer cells mainly interact with migratory hepatic paren-
chymal and non-parenchymal cells that have lost their
original position coordinates in the hepatic tissue organiza-
tion, and are recruited into the metastatic tissue to form the
tumor stroma. This stage corresponds to the angiogenic
phase of the hepatic metastasis process, and it implies the
transition from avascular to vascularized metastasis.
Lesions can be detectable by non-invasive methods [94],
but their existence is still subclinical because metastasis
size ranges from 0.3 up to 5 mm. These metastases have the
potential of becoming clinically relevant and, if multifocal,
they may affect liver functions and hemodynamics. Thera-
peutic targets at this stage are cancer cell invasion and
proliferation-stimulating factors, and mediators of tumor-
induced angiogenesis and stromagenesis.
Hepatic Metastasis Stage III When liver-infiltrating cancer
cells have formed a clinically detectable established
metastasis, bigger than 5 mm in diameter, whose develop-
ment is no longer affected by hepatic tissue organization.
This is the most advanced stage of the hepatic metastasis
process. It involves the whole hepatic organ, to which it
affects through the secretion of tumor-derived factors, and it
progressively alters in terms of tissue structure, blood
supply and metabolic substrate availability, jeopardizing
parenchymal cell function. However, at this stage, hepatic
metastases are still microenvironmentally modulated. On
the one hand, metastases contain tumor-infiltrating lym-
phocytes [95]—including immunosuppressant CD4/CD25
regulatory T cells [90]—and stromal cells mainly derived
from hepatic tissue [96], and whose specific phenotypes
have prognostic implications. On the other hand, both
normal and cancer cells within metastatic tissue are also
transcriptionally affected by hepatic soluble factors, includ-
ing proinflammatory and angiogenic cytokines [56, 97],
type I-insulin-like growth factor [98], and immunosuppres-
sant factors (TGFbeta, IL-10, soluble ICAM-1, etc), whose
elevated concentration also have regulatory effects. There-
fore, at this stage established hepatic metastases are affected
again by two interrelated microenvironments whose control
may require different therapeutic approaches: parenchymal
and non-parenchymal cells from tumor-unaffected hepatic
areas, and tumor-activated hepatic cells recruited into the
metastatic tissue.
In summary, besides its natural antitumor defense
mechanisms, the liver has prometastatic effects accounting
for the high incidence and aggressiveness of hepatic
metastasis. Our growing knowledge on the molecular basis
of hepatic metastasis regulation by microenvironment
opens new avenues for hepatic metastasis prevention at a
subclinical stage, and for treatment at more advanced
stages. In addition, together with possible metastasis-related
gene profiles revealing the existence of liver metastatic
potential in primary tumors, some genes from metastatic
cells are hepatic cell-dependent and, therefore, new bio-
markers of the specific biologic background of the liver
supporting its prometastatic microenvironment are needed
for the individual assessment of hepatic metastasis risk in
cancer patients.
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